PolyPid Ltd. (PYPD) News

PolyPid Ltd. (PYPD): $6.25

-0.15 (-2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter PYPD News Items

PYPD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PYPD News Highlights

  • PYPD's 30 day story count now stands at 3.
  • Over the past 14 days, the trend for PYPD's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest PYPD News From Around the Web

Below are the latest news stories about PolyPid Ltd that investors may wish to consider to help them evaluate PYPD as an investment opportunity.

JMP Securities Thinks PolyPid’s Stock is Going to Recover

JMP Securities analyst Roy Buchanan reiterated a Buy rating on PolyPid (PYPD – Research Report) today and set a price target of $15.00. The company's shares closed last Wednesday at $4.15, close to its 52-week low of $4.01. According to TipRanks.com, Buchanan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.3% and a 32.0% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma. Currently, the analyst consensus on PolyPid is a Moderate Buy with an average price target of $22.50.

Brian Anderson on TipRanks | February 9, 2022

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up• Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery. Expect to Reach 750 Enrolled Patients by End of First Quarter 2022 and Have Unblinded Interim Analysis During the Second Quarter of 2022• Recently Completed Planned 500-Patient Blinded Sample Size Reasses

Yahoo | February 9, 2022

PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a confe

Yahoo | January 26, 2022

PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Be

Yahoo | January 4, 2022

PolyPid Announces Planned CEO Transition

Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company’s Executive Vice President and Chief F

Yahoo | January 3, 2022

How Much Of PolyPid Ltd. (NASDAQ:PYPD) Do Insiders Own?

A look at the shareholders of PolyPid Ltd. ( NASDAQ:PYPD ) can tell us which group is most powerful. Generally...

Yahoo | December 27, 2021

PolyPids (PYPD) Buy Rating Reiterated at JMP Securities

JMP Securities reissued their buy rating on shares of PolyPid (NASDAQ:PYPD) in a report issued on Thursday morning, Analyst Ratings Network reports. JMP Securities currently has a $15.00 price objective on the stock. Separately, Zacks Investment Research upgraded shares of PolyPid from a hold rating to a buy rating and set a $8.50 target price []

Dakota Financial News | December 19, 2021

10 Micro-Cap Stocks to Buy According to Cathie Wood

In this article, we discuss the 10 micro-cap stocks to buy according to Cathie Wood. If you want to skip our detailed analysis of Cathie Wood’s investment philosophy and hedge fund performance, go directly to the 5 Micro-Cap Stocks to Buy According to Cathie Wood. Cathie Wood, the ARK Investment Management CEO, has been known […]

Yahoo | December 14, 2021

PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 30.0% in October

PolyPid Ltd. (NASDAQ:PYPD) was the target of a large growth in short interest during the month of October. As of October 29th, there was short interest totalling 28,200 shares, a growth of 30.0% from the October 14th total of 21,700 shares. Currently, 0.2% of the shares of the company are sold short. Based on an []

Transcript Daily | November 21, 2021

Brokerages Expect PolyPid Ltd. (NASDAQ:PYPD) Will Announce Earnings of -$0.52 Per Share

Equities analysts expect PolyPid Ltd. (NASDAQ:PYPD) to announce ($0.52) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for PolyPids earnings. PolyPid posted earnings per share of ($0.41) during the same quarter last year, which suggests a negative year over year growth rate of 26.8%. The []

Dakota Financial News | November 20, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.465 seconds.